Alterity醫療 ATHE 深 滬
等待開盤 05-19 09:30:00 美东时间
4.335
+0.305
+7.57%
華盛通- 最 高4.4799
- 今 開4.25
- 成交量 1.81万股
- 最 低 4.25
- 昨 收 4.03
- 總市值 7857.49万
- 52周最高 7.00
- 市盈率 靜 --
- 換手率 0.10%
- 52周最低 2.66
- 委 比 70.46%
- 總股本 1812.57万
- 歷史最高 51.50
- 量 比 0.54
- 振 幅 5.70%
- 歷史最低 1.001
- 每 手 1
- 風險率 0.70%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Alterity Therapeutics Showcases MSA Program Ahead of Phase 3 Push
Alterity Therapeutics ( ($AU:ATH) ) has shared an announcement. Alterity Therap...
05-07 09:42
Alterity Therapeutics Receives Positive FDA Feedback Following A Type C Meeting Regarding Its Planned Phase 3 Development Program For ATH434 In Multiple System Atrophy, A Rare, Rapidly Progressive Neurodegenerative Disease With No Approved Disease-Modifying Treatments
This second Type C Meeting builds on Alterity's recent regulatory interactions with the FDA and represents a further step towards readiness for the planned Phase 3 pivotal trial in MSA. Alterity received written feedback
04-27 19:28
Alterity to Spotlight ATH434 MSA Data in Late-Breaker at AAN Meeting
Alterity Therapeutics ( ($AU:ATH) ) has shared an announcement. Alterity Therap...
04-16 10:42
Alterity Flags Risks Around Forward‑Looking Corporate Outlook
The latest announcement is out from Alterity Therapeutics ( ($AU:ATH) ). Alteri...
04-01 13:28
Alterity Therapeutics Receives Positive Regulatory Feedback Following Type C Meeting With FDA Regarding Planned Phase 3 Development Program For ATH434 In MSA
Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced it has received
03-30 19:26
Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program
Alterity Therapeutics announced positive feedback from the FDA after a Type C Meeting regarding its Phase 3 development program for ATH434 in treating Multiple System Atrophy (MSA). The feedback supports the clinical pharmacology and non-clinical elements of the program. Alterity plans to seek agreement with the FDA on Chemistry, Manufacturing, and Controls (CMC) and the Phase 3 trial design, aiming for an End-of-Phase 2 meeting in mid-2026. ATH4...
03-30 11:25
Alterity Therapeutics Highlights Late-Stage Neurodegenerative Pipeline at Bell Potter Summit
Alterity Therapeutics ( ($AU:ATH) ) has shared an announcement. Alterity Therap...
03-09 08:52
Alterity Therapeutics appoints Daniel O. Claassen as Chief Medical Advisor
Alterity Therapeutics appoints Daniel O. Claassen as Chief Medical Advisor Alterity Therapeutics Ltd. has appointed Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor, with the role starting in March 2026. Claassen will retain his academic appointment at Vanderbilt University Medical Center wh
03-04 19:04
Alterity Therapeutics Appoints Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor
Alterity Therapeutics appoints Daniel O. Claassen, M.D., as Chief Medical Advisor to enhance expertise in neurodegenerative diseases, particularly Multiple System Atrophy (MSA). With over two decades of experience in movement disorders and clinical trials, Dr. Claassen will guide the Phase 3 trial for ATH434, building on his role as coordinating investigator in the Phase 2 study. Alterity, a biotech focused on neurodegenerative treatments, antici...
03-04 12:25
